Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; none of the 43 sources its claims cite is checked for support yet.
Abstract
Ethiopia has experienced a substantial resurgence in malaria in recent years, with increasing case numbers and a growing contribution of Plasmodium vivax in several regions. At the same time, new evidence supporting improved radical cure strategies, including high-dose primaquine and single-dose tafenoquine, alongside advances in molecular tools, offers opportunities to address persistent transmission and relapse. Against a backdrop of constrained funding and health system challenges, a stakeholder meeting was convened in Addis Ababa in November 2025 to review emerging evidence and discuss implications for malaria control and elimination in Ethiopia. The two-day meeting brought together 38 representatives from the National Malaria Control Programme, research institutions, regional health bureaus, and implementation partners. Key themes emerging from the meeting included: (i) systemic challenges shaping malaria control, including funding constraints, operational disruptions, and climate-related pressures; (ii) uncertainty around the contribution of relapse to overall P. vivax burden and the potential role of molecular tools to address this gap; (iii) important health system considerations for the introduction of G6PD-guided radical cure, particularly regarding service delivery levels and equity; (iv) the central role of economic evidence, with substantial uncertainty around drug pricing and implementation costs; and (v) the need for strengthened collaboration between researchers and policymakers to support evidence-informed decision-making. The meeting highlighted that, while more effective tools for P. vivax radical cure are available, their adoption in Ethiopia will depend on addressing key evidence gaps, particularly around relapse burden, feasibility, and cost-effectiveness. Given the current challenges, there is a pressing need for context specific research and continued dialogue between stakeholders, which will be critical to inform policy decisions and support progress towards malaria elimination.
Overview
CoChat Summary
TL;DR
This meeting report summarizes a November 2025 Addis Ababa stakeholder meeting on Ethiopia’s malaria resurgence and *Plasmodium vivax* radical cure, attended by 38 representatives. It concludes that high-dose primaquine, single-dose tafenoquine, and molecular tools are promising, but adoption depends on unresolved evidence gaps around relapse burden, feasibility, and cost-effectiveness.
Key findings
- Ethiopia’s malaria burden rose from 900,000 recorded cases in 2019 to between 7.3 and 12 million cases in 2024; Ethiopia alone accounted for roughly one-third of the global increase from 2023 to 2024, and *P. vivax* contributed over 40% of cases in Amhara, >30% in Tigray, and 10–25% in Somali and Dire Dawa.
- Ethiopia currently uses low-dose primaquine (3.5 mg/kg total dose over 14 days) without G6PD testing, but evidence supports high-dose primaquine (7 mg/kg total dose) and single-dose tafenoquine (300 mg); the national programme does not yet prioritize these due to cost concerns and uncertainty about relapse versus new infections.
- Health-system delivery is uncertain: national policy expects about 70% of malaria cases to be diagnosed and treated at health posts and 30% at health centres, but G6PD-guided radical cure may be challenging at health posts, and some areas report up to 70% of patients seeking care at health centres.
- Economic evidence was central: preliminary modelling suggested tafenoquine could be cost-saving versus high-dose primaquine under some assumed procurement prices, but this reversed under alternative prices; stakeholders preferred a societal perspective and malaria cases averted as the primary outcome, while no consensus emerged on modelling intermediate G6PD activity or day 3 review visits.
Methods
- A two-day stakeholder meeting, “Building the toolkit to address malaria resurgence and radical cure in Ethiopia,” was held on 28–29 November 2025 in Addis Ababa and convened 38 representatives from the National Malaria Control Programme, Ethiopian research institutions, five regional malaria focal persons (Amhara, Tigray, Somali, Gambella, and Dire Dawa), and implementation partners.
- Day 1 covered malaria priorities and resurgence, radical cure evidence, and operational/economic considerations, including an interactive Mentimeter question-and-answer session; Day 2 focused on practical use cases for molecular tools, with short presentations followed by moderated roundtable discussions.
- Notes were taken and collated to present key discussion points; the report synthesizes themes qualitatively and does not report primary data collection or statistical analysis.
Limitations
- The authors state that molecular tools to distinguish relapse from reinfection are not yet fully validated and remain confined to academic research; there are no validated molecular markers for *P. vivax* drug resistance, including chloroquine, and sampling, cost, and classification uncertainty remain.
- The authors note substantial uncertainty around primaquine and tafenoquine costs, no consensus on modelling intermediate G6PD activity or follow-up visits, and no explicit cost-effectiveness threshold for Ethiopia.
- Evident from the text: as a meeting report, the findings reflect stakeholder discussion and personal communication rather than a systematic review or primary study, and no formal consensus or quantitative synthesis is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
0 Valid · 0 Not valid · 22 Not checked · 9 Own results and interpretations
None of the sources cited for this claim have been checked yet.
In the paper
“Recent multi-country pooled analyses have demonstrated that a high total dose of primaquine (7 mg/kg) provides substantially greater protection against relapse compared with the low-dose (3.5 mg/kg total dose) regimen [8, 9]”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > Introduction
What the sources say
- Not checked yetcites [8] Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172–83. source
- Not checked yetcites [9] Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:184–95. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In another trial, where individuals were treated with or without primaquine [31], genotyping demonstrated a lower frequency of suspected relapses in patients treated with primaquine compared to those without [30].”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > Introduction
What the sources say
- Not checked yetcites [31] Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299. source
- Not checked yetcites [30] Kleinecke M, Sutanto E, Rumaseb A, Hoon KS, Trimarsanto H, Osborne A, et al. Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages. Nat Commun. 2025;16:7192. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This relationship reversed under alternative price scenarios.”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > Cost considerations and the role of economic evidence
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
None of the sources cited for this claim have been checked yet.
In the paper
“Recently, however, the country has experienced a substantial resurgence in malaria, with national case numbers increasing from 900,000 recorded cases in 2019 to between 7.3 and 12 million cases in 2024 [1, 2].”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > Introduction
What the sources say
- Not checked yetcites [1] Organization WH: Disease Outbreak News; Malaria in Ethiopia. 2024.
- Not checked yetcites [2] WHO: World malaria report 2024. 2024.
plainstates a causen = 12- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“P. vivax genotyping samples from these trials provides important proof of concept for the ability of molecular surveillance to inform on relapse burden in not only clinical trials but also potentially broader surveillance frameworks to inform on drivers of resurgence and reservoirs of transmission before and after intervention changes [32].”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > Introduction
What the sources say
- Not checked yetcites [32] Rosado J, Han J, Obadia T, Munro J, Traore Z, Schoffer K, Brewster J, Bourke C, Vinetz JM, White M, et al. Understanding Plasmodium vivax recurrent infections using an amplicon deep sequencing assay, PvAmpSeq, identity-by-descent and model-based classification. medRxiv 2025. source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 31 claims and to verify the 40 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2024, Ethiopia accounted for approximately 97% of the P. vivax burden in Africa, with P. vivax infections becoming more prevalent in areas of the country that were previously dominated by P. falciparum [1,18].”
From Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins (2026) · cites this paper as [18]
In the citing paper
“The southern area of Arba Minch has, however, historically been associated with higher transmission intensity [1,18,29].”
From Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins (2026) · cites this paper as [18]
In the citing paper
“Our results are not intended to minimise safety concerns, but to provide previously unavailable molecular evidence that not only highlight the true burden of the untreated hypnozoite reservoir in Ethiopia.but also add weight to an economic analysis that will inform policy and cost allocation decisions for the expansion of safe radical cure in Ethiopia and other P. vivax endemic areas [18].”
From Plasmodium vivax relapse reservoirs in Ethiopia: microhaplotype sequencing informs recurrent infection origins (2026) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > References
“Front Genet. 2018;15:1478706.”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > References
“Genetic surveillance shows spread of ACT resistance during period of malaria decline in Vietnam (2018-2020).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > References
“BMC Health Serv Res. 2020;25:928.”
§ Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report > References
“Exploring health system challenges and gaps for crisis response in Ethiopia: a scoping review of publications and reports from 2020-2024.”
Citations
Cites
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
Lacerda, M. V. G., Llanos-Cuentas, A., Krudsood, S., Lon, C., Saunders, D. L., Mohammed, R., Yilma, D., Batista Pereira, D., Espino, F. E. J., Mia, R. Z., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1710775 · Cited by 260
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
Llanos-Cuentas, A., Lacerda, M. V. G., Hien, T. T., Vélez, I. D., Namaik-larp, C., Chu, C. S., Villegas, M. F., Val, F., Monteiro, W. M., Brito, M. A. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1802537 · Cited by 236
Amato, R., Pearson, R. D., Almagro-Garcia, J., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Drury, E., Stalker, J., Miotto, O., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30068-9 · Cited by 221
Taylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Chau, N. H., Cheah, P. Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31285-1 · Cited by 178
Self-citationTessema, S., Wesolowski, A., Chen, A., Murphy, M., Wilheim, J., Mupiri, A.-R., Ruktanonchai, N. W., Alegana, V. A., Tatem, A. J., Tambo, M., et al. (2019) · eLife · doi:10.7554/elife.43510 · Cited by 124
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically
Taylor, A. R., Watson, J. A., Chu, C. S., Puaprasert, K., Duanguppama, J., Day, N. P. J., Nosten, F., Neafsey, D. E., Buckee, C. O., Imwong, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13412-x · Cited by 118
Donnelly, M. J., Isaacs, A. T., & Weetman, D. (2016) · Trends in Parasitology · doi:10.1016/j.pt.2015.12.001 · Cited by 117
Mapping imported malaria in Bangladesh using parasite genetic and human mobility data
Chang, H.-H., Wesolowski, A., Sinha, I., Jacob, C. G., Mahmud, A., Uddin, D., Zaman, S. I., Hossain, M. A., Faiz, M. A., Ghose, A., et al. (2019) · eLife · doi:10.7554/elife.43481 · Cited by 112
Jacob, C. G., Thuy-Nhien, N., Mayxay, M., Maude, R. J., Quang, H. H., Hongvanthong, B., Vanisaveth, V., Ngo Duc, T., Rekol, H., van der Pluijm, R., et al. (2021) · eLife · doi:10.7554/elife.62997 · Cited by 110
Abreha, T., Hwang, J., Thriemer, K., Tadesse, Y., Girma, S., Melaku, Z., Assef, A., Kassa, M., Chatfield, M. D., Landman, K. Z., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002299 · Cited by 82
Self-citation
Cited by
Osborne, A. A., Ruybal-Pesantez, S., Rai, A., Trimarsanto, H., Hoon, K. S., Piera, K., Kleinecke, M., Rumaseb, A., Sutanto, E., Thriemer, K., et al. (2026) · doi:10.64898/2026.11.12.765293
Self-citation
Metadata
- Authors
- Degaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., Puoch, K., Abdelmenan, S., Mesfin, M., Hailemichael, Y., Gadisa, E., Hailu, D., Beyene, E., Lankir, D., Teklu, G., Mamo, H., Amare, E., Etana, K., Temesgen, Y., Nigusse, B., Adissu, W., Hailu, A., Yewhalaw, D., Kebede, A., Abanegash, J., Teka, H., Legese, S., Getachew, A., Abdi, B., Minale, M., Abera, A., Tasew, G., Tafess, K., Sisay, A., Seyoum, N., Dilu, D., Aliyi, A., Devine, A., Assefa, A., Auburn, S., & Thriemer, K.
- Affiliations
- Charles Darwin University (AU)
- Ethiopian Public Health Institute (ET)
- Arba Minch University (ET)
- Program for Appropriate Technology in Health (US)
- Addis Continental Institute of Public Health (ET)
- Armauer Hansen Research Institute (ET)
- Amhara Regional Health Bureau (ET)
- Aksum University (ET)
- Addis Ababa University (ET)
- Federal Ministry of Health (ET)
- Jimma University (ET)
- Adama Science and Technology University (ET)
- The University of Melbourne (AU)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Thriemer, Kamala
- ORCID
- Degaga, Tamiru Shibiru
- Sime, Heven
- Osborne, Ashley
- Mwaura, Muthoni
- Bamboro, Samuel Alemu
- Abdelmenan, Semira
- Hailemichael, Yohannes
- Gadisa, Endalamaw
- Mamo, Hassen
- Adissu, Wondimagegn
- Yewhalaw, Delenasaw
- Teka, Hiwot
- Abera, Adugna
- Tasew, Geremew
- Tafess, Ketema
- Sisay, Abay
- Devine, Angela
- Assefa, Ashenafi
- Auburn, Sarah
- Thriemer, Kamala
- Venue
- Malaria Journal
- Published
- 2026-07-31
- Volume
- 25
- Issue
- 1
- Pages
- 278
- ISSN
- 1475-2875 (ISSN-L)
- PMC
- PMC13425933
- OpenAlex
- W7171842801
- Semantic Scholar
- bc1654c7c03610d860c392c1f9d53fdea9200ebe
- Cited by
- 1
- References
- 33
- Citations by year
- 2026: 1
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Malaria Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Bill and Melinda Gates Foundation (INV-043618, INV-024389)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Social Sciences › Arts and Humanities › History › History of Medicine and Tropical Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Keywords
- malaria resurgence, Plasmodium vivax, radical cure, primaquine, tafenoquine, relapse, glucose-6-phosphate dehydrogenase, malaria elimination, malaria control, health system challenges, drug pricing, cost-effectiveness, evidence-informed policy, Ethiopia
- MeSH terms
- Antimalarials, Ethiopia, Humans, Plasmodium vivax, Malaria, Vivax, Communicable Diseases, Emerging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report. https://app.cochat.ai/papers/10.1186/s12936-026-06050-4
- The paper
- Degaga, T. S., Sime, H., Ruybal-Pesántez, S., Osborne, A., Mwaura, M., Bamboro, S. A., Mnjala, H., Mekonnen, G., Ermias, S., Fantahun, A., Puoch, K., Abdelmenan, S., Mesfin, M., Hailemichael, Y., Gadisa, E., Hailu, D., Beyene, E., Lankir, D., Teklu, G., . . . Thriemer, K. (2026). Building the toolkit to address malaria resurgence and radical cure of vivax malaria in Ethiopia: a meeting report. Malaria Journal. https://doi.org/10.1186/s12936-026-06050-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
